Literature DB >> 27668667

Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis.

Xiao-Yan Qin1, Shu-Ping Zhang1, Chang Cao1, Y Peng Loh2, Yong Cheng2.   

Abstract

IMPORTANCE: The association of nonmotor features and Parkinson disease (PD) is increasingly recognized. Evidence suggests that inflammation may play a role in PD pathologic features and symptoms.
OBJECTIVE: To quantitatively summarize the peripheral inflammatory cytokine data available for patients with PD. DATA SOURCE: A systematic search of peer-reviewed English-language articles from PubMed, PsycINFO, and the Cochrane Library without year limitation was performed from December 7, 2015, to March 23, 2016. The search terms included inflammation or cytokine or chemokine or tumor necrosis factor or interleukin or interferon or C-reactive protein AND Parkinson disease. STUDY SELECTION: Studies were included if they provided data on peripheral blood cytokine concentrations in patients with PD and a healthy control group. Studies were excluded if they contained in vitro analysis of stimulated or unstimulated levels of cytokines, samples that overlapped with other studies, patients not diagnosed with PD at blood sampling, or if the cytokine analyzed was assessed in fewer than 3 studies. DATA EXTRACTION AND SYNTHESIS: Data were extracted from the 25 included studies encompassing 1547 unique patients with PD and 1107 unique controls by 2 independent investigators. Data were pooled using a random-effects model with the Comprehensive Meta-analysis software. Effect sizes were generated as standardized mean differences of cytokine concentrations between patients with PD and healthy controls and converted to the Hedges g statistic. MAIN OUTCOMES AND MEASURES: Blood cytokine concentrations in patients with PD compared with controls. Aberrations in peripheral cytokine levels were hypothesized to be related to PD.
RESULTS: Among the 2654 study participants, concentrations of interleukin 6 (IL-6) (Hedges g, 0.325; 95% CI, 0.007-0.643; P = .045) in 13 studies, tumor necrosis factor (Hedges g, 0.354; 95% CI, 0.144-0.563; P = .001) in 9 studies, IL-1β (Hedges g, 0.382; 95% CI, 0.142-0.621; P = .002) in 6 studies, C-reactive protein (Hedges g, 0.323; 95% CI, 0.052-0.593; P = .02) in 6 studies, IL-10 (Hedges g, 0.329; 95% CI, 0.051-0.607; P = .02) in 5 studies, RANTES (regulated on activation, normal T-expressed, and presumably secreted) (Hedges g, 0.605; 95% CI, 0.111-1.099; P = .02) in 5 studies, and IL-2 (Hedges g, 0.789; 95% CI, 0.105-1.472; P = .02) in 3 studies were significantly higher in patients with PD compared with healthy controls. No differences were found between patients with PD and healthy controls for concentrations of interferon-γ (Hedges g, 0.745; 95% CI, -0.192 to 1.682; P = .12) in 5 studies, IL-4 (Hedges g, 0.031; 95% CI, -0.191 to 0.253; P = .79) in 3 studies, and IL-8 (Hedges g, 0.072; 95% CI, -0.136 to 0.279; P = .50) in 3 studies. CONCLUSIONS AND RELEVANCE: The findings of the meta-analysis demonstrated higher peripheral concentrations of IL-6, tumor necrosis factor, IL-1β, IL-2, IL-10, C-reactive protein, and RANTES in patients with PD, strengthening the clinical evidence that PD is accompanied by an inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27668667     DOI: 10.1001/jamaneurol.2016.2742

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  135 in total

Review 1.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

Review 2.  Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms.

Authors:  Arthi Kanthasamy; Huajun Jin; Adhithiya Charli; Anantharam Vellareddy; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

3.  Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.

Authors:  Daniella Balduino Victorino; Mariana Nejm; Marcia Guimarães-Marques; Fulvio Alexandre Scorza; Carla Alessandra Scorza
Journal:  Pharmaceut Med       Date:  2021-01-07

Review 4.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

5.  Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries.

Authors:  Alejandra Camacho-Soto; Anat Gross; Susan Searles Nielsen; Neelendu Dey; Brad A Racette
Journal:  Parkinsonism Relat Disord       Date:  2018-02-09       Impact factor: 4.891

6.  Interleukin 6 and complement serum level study in Parkinson's disease.

Authors:  Branislav Veselý; Michal Dufek; Vojtech Thon; Miroslav Brozman; Silvia Királová; Tatiana Halászová; Eva Koriťáková; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2018-02-12       Impact factor: 3.575

7.  A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study.

Authors:  Riccardo Calvani; Anna Picca; Giovanni Landi; Federico Marini; Alessandra Biancolillo; Hélio José Coelho-Junior; Jacopo Gervasoni; Silvia Persichilli; Aniello Primiano; Annalaura Arcidiacono; Andrea Urbani; Maurizio Bossola; Anna Rita Bentivoglio; Matteo Cesari; Roberto Bernabei; Maria Rita Lo Monaco; Emanuele Marzetti
Journal:  Geroscience       Date:  2020-05-26       Impact factor: 7.713

8.  Cerebrospinal Fluid C-Reactive Protein in Parkinson's Disease: Associations with Motor and Non-motor Symptoms.

Authors:  Hossein Sanjari Moghaddam; Zahra Valitabar; Amir Ashraf-Ganjouei; Mahtab Mojtahed Zadeh; Farzaneh Ghazi Sherbaf; Mohammad Hadi Aarabi
Journal:  Neuromolecular Med       Date:  2018-07-06       Impact factor: 3.843

9.  Serum Lymphocyte-Associated Cytokine Concentrations Change More Rapidly over Time in Multiple System Atrophy Compared to Parkinson Disease.

Authors:  Keri Csencsits-Smith; Jessika Suescun; Kan Li; Sheng Luo; Diane L Bick; Mya Schiess
Journal:  Neuroimmunomodulation       Date:  2017-04-11       Impact factor: 2.492

Review 10.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.